Info

🌱 來自：Monoclonal Antibodies

Elotuzumab

• Mechanism: Binds to the signaling lymphocytic activation molecule family member 7 (SLAMF7)
• Dosing:
  • Cycle 1-2 given in combination w/ lenalidomide & dexamethasone or pomalidomide & dexamethasone: 10 mg/kg IV once weekly on a 28-d cycle;
  • cycle 3 & more given in combination w/ lenalidomide & dexamethasone: 10 mg/kg IV every 2 wks of a 28-d cycle;
  • cycle 3 & more given in combination w/ pomalidomide & dexamethasone: 20 mg/kg IV every 4 wks of a 28-d cycle. Withhold or discontinue tx for toxicity (hepatic & infusion rxns)
• PK/PD: T1/2 ∼82 d
• AEs:
  • Fatigue,
  • high blood pressure,
  • diarrhea,
  • ↓ Ca,
  • leukopenia,
  • thrombocytopenia,
  • ↑ alk phos,
  • hepatotoxicity,
  • ↑ blood glucose,
  • infxn,
  • infusion rxns,
  • 2° malignancy
• DDI: No known pathways of metabolism, avoid live & inactivated vaccines
• Clinical pearls:
  • Antiviral ppx should be started prior to tx,
  • requires premedication,
  • can interfere w/ assays for M-protein monitoring